financetom
Business
financetom
/
Business
/
Roku's quarterly revenue beats estimates on strong ad sales
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roku's quarterly revenue beats estimates on strong ad sales
Feb 13, 2025 1:33 PM

(Reuters) -Roku ( ROKU ) topped Wall Street estimates for fourth-quarter revenue on Thursday, driven by robust subscriber growth and strong advertising sales.

Shares of the firm rose 9.7% in trading after the bell.

Roku ( ROKU ) has expanded its advertising offerings to small- and medium-sized businesses, leveraging its home screen to diversify revenue streams across sectors.

Brands from retail, automotive and telecom now feature their ads in the platform, enhancing visibility and boosting user engagement. This move allows businesses to tap into Roku's ( ROKU ) extensive user base.

The surge in political ad spending and Roku's ( ROKU ) growing subscriber base have boosted its advertising revenue and audience reach, driving overall growth.

The company's platform segment, which derives revenue from ad sales and subscriptions, grew 25% to $1.04 billion due to advertising activities, particularly from the political vertical.

Ahead of the results, Barton Crockett from Rosenblatt said: "Political advertising on connected TV (CTV) stepped up meaningfully this cycle versus the last cycle, in part because of a big push into the medium by Kamala Harris."  

The company reported revenue of $1.20 billion in the fourth quarter, compared to the analysts' average estimate of $1.15 billion, according to data compiled by LSEG.   

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BTU Dixie East Project Approved
BTU Dixie East Project Approved
Oct 27, 2025
VANCOUVER, BC / ACCESS Newswire ( ACCS ) / October 27, 2025 / BTU METALS CORP. ( BTUMF ) (BTU or the Company) (OTCQB:BTUMF) is pleased to announce the acquisition of the 100% interest in the newly secured Dixie East Project, a large and strategically located land package immediately east of Kinross Gold's ( KGCRF ) world-renowned Great Bear Dixie...
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Oct 27, 2025
Oct 27 (Reuters) - Organon said on Monday CEO Kevin Ali will resign from his role, after an internal investigation into sales of its Nexplanon contraceptive implant to wholesalers pointed to improper practices. An audit committee found certain U.S. wholesalers were asked to purchase more Nexplanon than needed at the end of several quarters between 2022 and 2025. While the...
Intellia Therapeutics Pauses Dosing in Phase 3 Trials After Grade 4 Liver Transaminases Reported in Participant
Intellia Therapeutics Pauses Dosing in Phase 3 Trials After Grade 4 Liver Transaminases Reported in Participant
Oct 27, 2025
08:01 AM EDT, 10/27/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Monday it has paused patient dosing and screening for its two phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy, respectively, after a patient was reported with Grade 4 liver transaminases and increased total bilirubin after dosage with the drug. The...
Johnson & Johnson Says 2-Year Data for Tremfya in Crohn's Disease Shows Durable Remission
Johnson & Johnson Says 2-Year Data for Tremfya in Crohn's Disease Shows Durable Remission
Oct 27, 2025
08:01 AM EDT, 10/27/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that long-term extensions of its phase 3 studies showed that its drug, Tremfya, maintained high rates of clinical and endoscopic remission in adults with moderately to severely active Crohn's disease through two years. The drugmaker said the studies evaluated patients who received either subcutaneous or...
Copyright 2023-2025 - www.financetom.com All Rights Reserved